与肺疾病相关的肺动脉高压:发病机制、诊断和管理的新见解
间质性肺疾病和慢阻肺患者常发生肺动脉高压,导致临床恶化、氧摄取能力下降和死亡风险增加。其肺血管病变以远端小血管丧失为关键特征,与其它类型肺动脉高压不同,多数肺动脉高压药物无效甚至有害,吸入曲前列尼尔例外。亟需安全有效的治疗选择和无创诊断工具。
要点
- 间质性肺疾病和慢阻肺患者常见肺动脉高压,增加死亡风险。
- 肺血管病变以远端小血管丧失为关键特征,长期烟草暴露可能参与。
- 多数肺动脉高压药物无效或有害,吸入曲前列尼尔可改善运动能力。
核心结论
- 与肺疾病相关的肺动脉高压是间质性肺疾病和慢阻肺的常见并发症,导致临床恶化和死亡风险增加。
- 其肺血管病变以远端小血管丧失为关键特征,发病机制独特,治疗选择有限。
- 吸入曲前列尼尔是唯一例外,可改善间质性肺疾病合并肺动脉高压患者的运动能力。
主要发现
- 间质性肺疾病和慢阻肺患者频繁发生肺动脉高压,导致临床恶化、氧摄取能力下降和死亡风险增加。
- 肺动脉高压可独立于基础肺疾病发生和进展。
- 肺血管病变与其它形式肺动脉高压不同,以远端小血管丧失为关键特征。
- 长期烟草暴露可能促进这种肺血管重塑。
- 多数肺动脉高压药物在肺疾病相关肺动脉高压中无效或有害,吸入曲前列尼尔例外。
临床怎么用
- 应关注间质性肺疾病和慢阻肺患者中肺动脉高压的发生,因其提示预后不良。
- 治疗选择有限,吸入曲前列尼尔可考虑用于间质性肺疾病合并肺动脉高压患者以改善运动能力。
- 亟需可靠的无创诊断工具来检测和表征慢性肺疾病患者的肺动脉高压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with chronic lung diseases, particularly interstitial lung disease and chronic obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in clinical deterioration, worsening of oxygen uptake, and an increased mortality risk. Pulmonary hypertension can develop and progress independently from the underlying lung disease. The pulmonary vasculopathy is distinct from that of other forms of pulmonary hypertension, with vascular ablation due to loss of small pulmonary vessels being a key feature. Long-term tobacco exposure might contribute to this type of pulmonary vascular remodelling. The distinct pathomechanisms together with the underlying lung disease might explain why treatment options for this condition remain scarce. Most drugs approved for pulmonary arterial hypertension have shown no or sometimes harmful effects in pulmonary hypertension associated with lung disease. An exception is inhaled treprostinil, which improves exercise capacity in patients with interstitial lung disease and pulmonary hypertension. There is a pressing need for safe, effective treatment options and for reliable, non-invasive diagnostic tools to detect and characterise pulmonary hypertension in patients with chronic lung disease.
引用
- Olsson KM, Corte TJ, Kamp JC, et al. Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management. Lancet Respir Med. 2023. PMID: 37591300. doi:10.1016/S2213-2600(23)00259-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。